Key result
In pathological hearts, the percentage of AT1 receptors decreases and AT2 receptors increases with cardiac dysfunction severity, while AT1 antagonists inhibit cardiac hypertrophy in rats.
The distribution and density of AT1 and AT2 receptors change with cardiac dysfunction, and AT1 receptor antagonists can inhibit cardiac hypertrophy in animal models.
No takes yet. Share an insight, caveat, or question.
No immediate practice change; leaves open whether AT1/AT2 remodeling guides targeted RAAS therapy in HF.
Gasparo et al. (1994) conducted a review in Cardiac dysfunction and cardiovascular disorders. AT1 receptor antagonists was evaluated. In pathological hearts, the percentage of AT1 receptors decreases and AT2 receptors increases with cardiac dysfunction severity, while AT1 antagonists inhibit cardiac hypertrophy in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: